| Cat.No. | Name | Information |
|---|---|---|
| M1825 | PCI-32765 | PCI-32765 (Ibrutinib) is a potent, selective and orally bioavailable irreversible inhibitor of BTK with IC50 value of 0.46 nM. |
| M5306 | Acalabrutinib | Acalabrutinib(ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.BMX, and TEC, respectively) and no activity against EGFR. |
| M5257 | ONO-4059 hydrochloride | ONO-4059 (GS-4059) hydrochloride is highly potent and selective BTK inhibitor with an IC50 of 2.2 nM. |
| M5162 | ONO-4059 analogue | ONO-4059 analogue is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with IC50 of 23.9 nM. |
| M3704 | RN486 | RN486 is a Bruton's tyrosine kinase (Btk) inhibitor with an IC50 Value of 4.0 nM. |
| M3620 | CGI1746 | CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM. |
| M2718 | GDC-0834 | GDC-0834 is a novel potent and selective BTK inhibitor with IC50 of 5.9 nM. |
| M2536 | CNX-774 | CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM. |
| M2113 | Spebrutinib (AVL-292) | Spebrutinib (AVL-292) is an oral, potent and selective small molecule covalent inhibitor of Btk (IC50 < 0.5 nM). |
| M54669 | TL-925 | TL-925 is a potentially first-in-class Bruton's tyrosine kinase (BTK) inhibitor that targets mast cell-mediated ocular inflammation and hypersensitivity and can be used in studies related to dry eye. |
| M49783 | JAK3/BTK-IN-6 | JAK3/BTK-IN-6 is a potent BTK and JAK3 dual inhibitor, with IC50 values of 0.6 and 0.4 nM, respectively. |
| M43478 | DBt-10 | DBt-10 is a potent BTK degrader. |
| M43477 | BTK-IN-27 | BTK-IN-27 is a BTK inhibitor (IC50: 0.2 nM). |
| M43476 | NRX-0492 | NRX-0492 is an orally active and potent degrader of BTK. |
| M43475 | PROTAC BTK Degrader-5 | PROTAC BTK degraders-5is a selective BTK degrader with a DC50 value of 7.0 nM in JeKo-1 cells. |
| M43474 | BTK-IN-25 | BTK-IN-25 is a potent inhibitor of BTK, and inhibits BTK(C481S) with an IC50 value of 0.77 nM. |
| M43473 | Cinsebrutinib | Cinsebrutinib is a Bruton's tyrosine kinase inhibitor, extracted from patent WO2021207549 (compound 5-6). |
| M43472 | BTK-IN-26 | BTK-IN-26 is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC50 values of 0.7 and 0.8 nM for BTK and BTK C481S, respectively. |
| M43406 | PROTAC BTK Degrader-6 | PROTAC BTK Degrader-6 is a PROTAC BTK degrader (DC50: 3.18 nM. |
| M40617 | TAS5315 | TAS5315 is a novel, irreversible covalent inhibitor of BTK for studies related to rheumatoid arthritis. |
| M29609 | JS25 | JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC50 value of 5.8 nM by chelating Tyr551. JS25 inhibits cancer cells proliferation, pronounces cell death, and promotes murine xenograft model of Burkitt’s lymphoma. JS25 effectively crosses the blood-brain barrier. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
